Latest Deltagen Inc (DGEN) Headlines Global M
Post# of 3
Posted On: 03/09/2014 2:28:48 PM
Latest Deltagen Inc (DGEN) Headlines
Global Mice Model Market Analysis, 2018: Type, Technology, Disease, Service & Care Products Breakdown
M2 - Fri Jan 10, 8:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/dgjm94/mice_model_market) has announced the addition of the "Global Mice Model Market Analysis, 2018" report to their offering. The global market (models and services) is valued at $1,115.2 million in 2013 and is expected to reach $1,819.9 million by 2018, growing at a CAGR of 10.3% from 2013 to 2018. The market for mice model services is segmented into breeding, cryopreservation, quarantine, rederivation, genetic testing, model in-licensing, and other services (surgical and line rescue). The biggest factor that is likely to drive the growth of this market is the ongoing innovations in the development of mice models. In addition, another factor that is likely to drive the growth of the market is the continuous research that is undertaken to develop treatments for fatal diseases such as cancer and HIV/AIDS. Furthermore, research institutes and government bodies have extended their help in the form of investments, funds, and grants, which have stimulated research activities to develop mice models. In addition, the demand for personalized medicines is expected to boost the use of humanized mice models. A number of factors such as advancements in the biotechnology and biopharmaceutical industries as well as the increase in the number of R&D activities in pharmaceutical industries are propelling the growth of the mice model market. However, stringent regulations and laws for ethical use of animals in research are hindering the growth of this market. In addition, the market is facing a threat from advances in zebrafish models and rat models, which are leading to their increased use in research activities. North America is the largest market for mice models, followed by Europe and Asia. Furthermore, the Asian and North American markets for mice models are expected to witness a healthy growth over the next five years. Scope of the Report Type - Inbred Mice - Outbred Mice - Conditioned/Surgically Modified Mice - Hybrid/Congenic Mice - Knockout Mice - Spontaneous Mutant Mice Technology - Microinjection - Embryonic Stem Cell Injection - Virus/Vector Mediated Gene Transfer - Nuclear transfer Technology - Genetically Modified Sperm - Others Disease - Oncology - Immunology & Inflammation - Central Nervous System - Cardiovascular - Diabetes - Metabolism & Regulation - Others Service - Breeding - Cryopreservation - Quarantine - Rederivation - Genetic Testing - Model In-licensing - Other Services (Surgical and Line Rescue) Mice Care Products - Bedding - Feed - Cages - Others Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Market Share Analysis, By Key Players 5 Mice Model Market Size 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles 9 Preclinical Pipeline 10 Industry Speaks 11 Cost Assessment and Mouse Model Outlicensing/Buyer Companies Assessment Companies Mentioned - Ablexis, LLC - Charles River Laboratories, Inc. - Covance, Inc. - Crescendo Biologics, - Deltagen, Inc. - Genoway Sa - Harbour Antibodies Bv - Harlan Laboratories, Inc. - Immunogenes Ag - Ingenious Targeting Laboratory - Lexicon Pharmaceuticals, Inc. - Mirimus, Inc. - Sage Labs - Taconic Farms, Inc. - The Jackson Laboratory - Transgenic, Inc. For more information visit http://www.researchandmarkets.com/research/dg...del_market
Deltagen Reports 2013 First Quarter Financial Results
Business Wire - Mon Oct 14, 5:00PM CDT
Deltagen, Inc. (Pink Sheets: DGEN), a provider of drug discovery tools and services to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended March 31, 2013.
Deltagen Reports 2012 Fourth Quarter and Full-Year Financial Results
Business Wire - Wed Apr 10, 5:00PM CDT
Deltagen, Inc. (Pink Sheets: DGEN), a leading provider of drug discovery tools and services to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months and year ended December 31, 2012.
Deltagen Reports 2012 Third Quarter Financial Results
Business Wire - Wed Jan 30, 5:00PM CST
Deltagen, Inc. (Pink Sheets: DGEN), a leading provider of drug discovery tools and services to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended September 30, 2012.
Global Mice Model Market Analysis, 2018: Type, Technology, Disease, Service & Care Products Breakdown
M2 - Fri Jan 10, 8:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/dgjm94/mice_model_market) has announced the addition of the "Global Mice Model Market Analysis, 2018" report to their offering. The global market (models and services) is valued at $1,115.2 million in 2013 and is expected to reach $1,819.9 million by 2018, growing at a CAGR of 10.3% from 2013 to 2018. The market for mice model services is segmented into breeding, cryopreservation, quarantine, rederivation, genetic testing, model in-licensing, and other services (surgical and line rescue). The biggest factor that is likely to drive the growth of this market is the ongoing innovations in the development of mice models. In addition, another factor that is likely to drive the growth of the market is the continuous research that is undertaken to develop treatments for fatal diseases such as cancer and HIV/AIDS. Furthermore, research institutes and government bodies have extended their help in the form of investments, funds, and grants, which have stimulated research activities to develop mice models. In addition, the demand for personalized medicines is expected to boost the use of humanized mice models. A number of factors such as advancements in the biotechnology and biopharmaceutical industries as well as the increase in the number of R&D activities in pharmaceutical industries are propelling the growth of the mice model market. However, stringent regulations and laws for ethical use of animals in research are hindering the growth of this market. In addition, the market is facing a threat from advances in zebrafish models and rat models, which are leading to their increased use in research activities. North America is the largest market for mice models, followed by Europe and Asia. Furthermore, the Asian and North American markets for mice models are expected to witness a healthy growth over the next five years. Scope of the Report Type - Inbred Mice - Outbred Mice - Conditioned/Surgically Modified Mice - Hybrid/Congenic Mice - Knockout Mice - Spontaneous Mutant Mice Technology - Microinjection - Embryonic Stem Cell Injection - Virus/Vector Mediated Gene Transfer - Nuclear transfer Technology - Genetically Modified Sperm - Others Disease - Oncology - Immunology & Inflammation - Central Nervous System - Cardiovascular - Diabetes - Metabolism & Regulation - Others Service - Breeding - Cryopreservation - Quarantine - Rederivation - Genetic Testing - Model In-licensing - Other Services (Surgical and Line Rescue) Mice Care Products - Bedding - Feed - Cages - Others Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Market Share Analysis, By Key Players 5 Mice Model Market Size 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles 9 Preclinical Pipeline 10 Industry Speaks 11 Cost Assessment and Mouse Model Outlicensing/Buyer Companies Assessment Companies Mentioned - Ablexis, LLC - Charles River Laboratories, Inc. - Covance, Inc. - Crescendo Biologics, - Deltagen, Inc. - Genoway Sa - Harbour Antibodies Bv - Harlan Laboratories, Inc. - Immunogenes Ag - Ingenious Targeting Laboratory - Lexicon Pharmaceuticals, Inc. - Mirimus, Inc. - Sage Labs - Taconic Farms, Inc. - The Jackson Laboratory - Transgenic, Inc. For more information visit http://www.researchandmarkets.com/research/dg...del_market
Deltagen Reports 2013 First Quarter Financial Results
Business Wire - Mon Oct 14, 5:00PM CDT
Deltagen, Inc. (Pink Sheets: DGEN), a provider of drug discovery tools and services to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended March 31, 2013.
Deltagen Reports 2012 Fourth Quarter and Full-Year Financial Results
Business Wire - Wed Apr 10, 5:00PM CDT
Deltagen, Inc. (Pink Sheets: DGEN), a leading provider of drug discovery tools and services to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months and year ended December 31, 2012.
Deltagen Reports 2012 Third Quarter Financial Results
Business Wire - Wed Jan 30, 5:00PM CST
Deltagen, Inc. (Pink Sheets: DGEN), a leading provider of drug discovery tools and services to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended September 30, 2012.
(0)
(0)